At a glance
ClinicalIndex Comparison Record- ✓Non-recurrent adenocarcinoma in Barrett's Esophagus confirmed by two experienced gastrointestinal pathologists
- ✓No evidence of submucosal invasion (T1a disease)
- ✓No evidence of metastatic disease in regional or distal lymph nodes or other organs
- ✓Pre-entry CT scans of upper abdomen and chest and Endoscopic Ultrasound (EUS) of tumor and regional lymph nodes required
- ✕Prior major esophageal surgery
- ✕Unable to tolerate endoscopic procedures
- ✕Uncontrolled diabetes, heart disease, or hypertension
- ✕Pregnant or lactating women, or men unable or unwilling to practice contraception
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Endoscopic Therapy of Early Cancer in Barretts Esophagus
In Brief
A Phase 2 clinical trial evaluating Endoscopic Mucosal Resection and Photodynamic Therapy for Early Stage Esophageal Adenocarcinoma and Barrett Esophagus. Completed, enrolled 73 participants across 1 site.
Detailed Summary
This study is being done to see if treatment for esophageal cancer can be done using endoscopy for patients ineligible for surgical or radiological therapy. The standard method of treating this type of cancer is surgical removal of the esophagus. The study will determine if removing just the cancer with endoscopy is enough treatment or if the addition of another treatment called photodynamic therapy (treatment with a red light and a drug called sodium porfimer) is needed.
Study Details
Timeline
Interventions
Endoscopic mucosal resection at time of endoscopy if indicated.
Porfimer sodium 2mg/kg